Abstract:Objective To analyze the association between rtA181S mutation in the reverse-transcriptase(RT) domain of HBV and adefovir dipivoxil(ADV) resistance. Methods Incidence of rtA181S mutation of HBV RT region was screened and analyzed from large samples of chronically HBV-infected patients by direct sequencing. Clonal sequencing was performed and drug- resistance-associated mutations were analyzed from the serum of an ADV-refractory patient with chronic hepatitis B. pGEM-Teasy RT plasmid and pTriEx-HBV(C) plasmid were digested and ligated by the restriction enzyme(XhoⅠ/SphⅠ), and the 1.1-ploid genome length HBV recombinant plasmids harboring wild-type and three kinds of mutants in RT region were constructed. Then the replication-competent constructs were transiently transfected into the HepG2 cells. Five hours post-transfection, new medium containing different concentrations of ADV(0, 0.033, 0.100, 0.330, 1.000, 3.300 μmol/L) was supplemented every other day for 4 days. To analyze the phenotypic characteristics of the HBV mutants under the drug pressure, the supernatant was collected and HBV DNA production was quantitated using real-time PCR. Results A total of 12 000 serum samples of 9830 patients with chronic HBV infection were screened. rtA181S mutation was detected in 46 nucleos(t)ide analogues-treated patients. By contrast, signature ADV- resistance mutations rtN236T and A181V were detected in 653 patients. The rtA181S emerged either alone or in concomitance with other drug-resistance mutations. A follow-up patient developed virological and biochemical breakthrough after 19-month ADV monotherapy. At the time of sampling, rtA181S+N236T was detected by direct sequencing. Clonal sequence analysis of 24 clones showed that there were 11(45.83%) for wild-type, 6(25.00%) for rtN236T, 5(20.83%) for rtA181S, 1(4.16%) for rtA181V, and 1(4.16%) for rtA181S+N236T. The relative viral replication capacity of rtN236T, rtA181S and rtA181S+N236T mutants was 91. 35%, 29.90% and 68.53% that of the wild-type strain, respectively. Phenotypic resistance analysis showed that ADV suscep- tibility of mutants harboring rtN236T, rtA181S and rtA181S +N236T was 1/4.41, 1/3.05, and 1/5.43 that of the wild-type strain. Conclusions rtA181S is an ADV-resistance-associated mutation, which may cause the drug resistance solely or with other mutations in patients with chronic HBV infection. Compared to signature ADV-resistance mutation, rtA181S mutation is less resistant and less frequently detected in ADV-resistance patients.

HBV Surface Proteins with Carboxyl Terminal Truncation Induced by Drug-Resistant Mutations of the Viral Reverse Transcriptase

Mutation and selective pressure of S gene in hepatitis B virus genotypes B & C in Jiangsu-Zhejiang-Shanghai area

[Sequence Detection of HBV-DNA P and C Region in HIV/HBV Superinfection Subjects with Drug Resistance to HAART].

Analysis of Rtv191i/sw182* Mutation in Chronic Hepatitis B Patients Treated with Nucleos/tide Analogues

A new vaccine escape mutant of hepatitis B virus causes occult infection.

Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients.

Higher Detection Rates of Amino Acid Substitutions in HBV Reverse Transcriptase/surface Protein Overlapping Sequence is Correlated with Lower Serum HBV DNA and HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Subgenotype B2

Impacts of HBV Rth55r Polymerase Substitution on Viral Replication and Rtm204i/v Resistance to Nucleoside/nucleotide Antiviral Drugs.

Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection

Discrepancy of Potential Antiviral Resistance Mutation Profiles Within the HBV Reverse Transcriptase Between Nucleos(t)ide Analogue‐untreated and ‐treated Patients with Chronic Hepatitis B in a Hospital in China

Small Surface Antigen Variants of HBV Associated with Responses to Telbivudine Treatment in Chronic Hepatitis B Patients

A Novel Reverse Transcriptase Mutation in Genotype C Hepatitis B Virus Associated with Rtm204i/v Drug Resistant Mutation

HBV multidrug resistant sW172* truncated variant possibly involve in the ER stress pathway during hepatocarcinogenesis.

Gene Heterogeneity of Hepatitis B Virus Isolates from Patients with Severe Hepatitis B.

Amino acid similarities and divergences in the small surface proteins of genotype C hepatitis B viruses between nucleos(t)ide analogue-naïve and lamivudine-treated patients with chronic hepatitis B

Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy

rtA181S mutation in the reverse-transcriptase domain of HBV is associated with adefovir dipivoxil resistance

High Prevalence of Tryptophan-Truncated S Quasispecies in Treatment-Naïve Chronic Hepatitis B Patients.

Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations

The genetic backbone modulates the phenotype of hepatitis B surface antigen mutants

Hepatitis B Virus X Mutations Affect Clinicopathological or Histopathological Characteristics in Patients with Chronic Hepatitis B Virus Infection